Björn Dahlöf, CMO, presents at the 18th Global Cardiovascular Clinical Trialists (CVCT) Forum

Björn Dahlöf, CMO, at the 18th CVCT Forum

Björn Dahlöf, CMO, presents study design for Cereno's Phase II study of drug candidate CS1 in pulmonary arterial hypertension (PAH) at the 18th CVCT Forum on December 4, 2021.

Watch here >